209 related articles for article (PubMed ID: 24619074)
1. Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer.
Rakha EA; Soria D; Green AR; Lemetre C; Powe DG; Nolan CC; Garibaldi JM; Ball G; Ellis IO
Br J Cancer; 2014 Apr; 110(7):1688-97. PubMed ID: 24619074
[TBL] [Abstract][Full Text] [Related]
2. Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.
Green AR; Soria D; Powe DG; Nolan CC; Aleskandarany M; Szász MA; Tőkés AM; Ball GR; Garibaldi JM; Rakha EA; Kulka J; Ellis IO
Breast Cancer Res Treat; 2016 May; 157(1):65-75. PubMed ID: 27116185
[TBL] [Abstract][Full Text] [Related]
3. Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series.
Green AR; Soria D; Stephen J; Powe DG; Nolan CC; Kunkler I; Thomas J; Kerr GR; Jack W; Cameron D; Piper T; Ball GR; Garibaldi JM; Rakha EA; Bartlett JM; Ellis IO
J Pathol Clin Res; 2016 Jan; 2(1):32-40. PubMed ID: 27499914
[TBL] [Abstract][Full Text] [Related]
4. Prognostic contribution of mammographic breast density and HER2 overexpression to the Nottingham Prognostic Index in patients with invasive breast cancer.
Masarwah A; Auvinen P; Sudah M; Dabravolskaite V; Arponen O; Sutela A; Oikari S; Kosma VM; Vanninen R
BMC Cancer; 2016 Nov; 16(1):833. PubMed ID: 27806715
[TBL] [Abstract][Full Text] [Related]
5. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index.
Callagy GM; Pharoah PD; Pinder SE; Hsu FD; Nielsen TO; Ragaz J; Ellis IO; Huntsman D; Caldas C
Clin Cancer Res; 2006 Apr; 12(8):2468-75. PubMed ID: 16638854
[TBL] [Abstract][Full Text] [Related]
6. Determination of GP88 (progranulin) expression in breast tumor biopsies improves the risk predictive value of the Nottingham Prognostic Index.
Serrero G; Hawkins DM; Bejarano PA; Ioffe O; Tkaczuk KR; Elliott RE; Head JF; Phillips J; Godwin AK; Weaver J; Hicks D; Yue B
Diagn Pathol; 2016 Aug; 11(1):71. PubMed ID: 27501955
[TBL] [Abstract][Full Text] [Related]
7. Novel secretome-to-transcriptome integrated or secreto-transcriptomic approach to reveal liquid biopsy biomarkers for predicting individualized prognosis of breast cancer patients.
Ankney JA; Xie L; Wrobel JA; Wang L; Chen X
BMC Med Genomics; 2019 May; 12(1):78. PubMed ID: 31146747
[TBL] [Abstract][Full Text] [Related]
8. Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?
Albergaria A; Ricardo S; Milanezi F; Carneiro V; Amendoeira I; Vieira D; Cameselle-Teijeiro J; Schmitt F
BMC Cancer; 2011 Jul; 11():299. PubMed ID: 21762477
[TBL] [Abstract][Full Text] [Related]
9. The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes.
El Ansari R; Craze ML; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Br J Cancer; 2018 Apr; 118(8):1115-1122. PubMed ID: 29545595
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
[TBL] [Abstract][Full Text] [Related]
11. Relationship of Oncotype Dx score with tumor grade, size, nodal status, proliferative marker Ki67 and Nottingham Prognostic Index in early breast cancer tumors in Saudi Population.
Durrani S; Al-Mushawa F; Heena H; Wani T; Al-Qahtani A
Ann Diagn Pathol; 2021 Apr; 51():151674. PubMed ID: 33360027
[TBL] [Abstract][Full Text] [Related]
12. Improving the Prognostic Ability through Better Use of Standard Clinical Data - The Nottingham Prognostic Index as an Example.
Winzer KJ; Buchholz A; Schumacher M; Sauerbrei W
PLoS One; 2016; 11(3):e0149977. PubMed ID: 26938061
[TBL] [Abstract][Full Text] [Related]
13. Classification of patients with breast cancer according to Nottingham prognostic index highlights significant differences in immunohistochemical marker expression.
Kurshumliu F; Gashi-Luci L; Kadare S; Alimehmeti M; Gozalan U
World J Surg Oncol; 2014 Aug; 12():243. PubMed ID: 25082024
[TBL] [Abstract][Full Text] [Related]
14. Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers.
Green AR; Powe DG; Rakha EA; Soria D; Lemetre C; Nolan CC; Barros FF; Macmillan RD; Garibaldi JM; Ball GR; Ellis IO
Br J Cancer; 2013 Oct; 109(7):1886-94. PubMed ID: 24008658
[TBL] [Abstract][Full Text] [Related]
15. Utilizing Nottingham Prognostic Index in microarray gene expression profiling of breast carcinomas.
Miller DV; Leontovich AA; Lingle WL; Suman VJ; Mertens ML; Lillie J; Ingalls KA; Perez EA; Ingle JN; Couch FJ; Visscher DW
Mod Pathol; 2004 Jul; 17(7):756-64. PubMed ID: 15073601
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Nottingham Prognostic Index, PREDICT and PrognosTILs in Triple Negative Breast Cancer -a Retrospective Cohort Study.
Sejben A; Nyári T; Zombori T; Cserni G
Pathol Oncol Res; 2020 Oct; 26(4):2443-2450. PubMed ID: 32564262
[TBL] [Abstract][Full Text] [Related]
17. A combination of Nottingham prognostic index and IHC4 score predicts pathological complete response of neoadjuvant chemotherapy in estrogen receptor positive breast cancer.
Tan W; Luo W; Jia W; Liang G; Xie X; Zheng W; Song E; Su F; Gong C
Oncotarget; 2016 Dec; 7(52):87312-87322. PubMed ID: 27894097
[TBL] [Abstract][Full Text] [Related]
18. A comparative analysis of recurrence risk predictions in ER+/HER2- early breast cancer using NHS Nottingham Prognostic Index, PREDICT, and CanAssist Breast.
Gunda A; Eshwaraiah MS; Gangappa K; Kaur T; Bakre MM
Breast Cancer Res Treat; 2022 Nov; 196(2):299-310. PubMed ID: 36085534
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution.
D'Eredita' G; Giardina C; Martellotta M; Natale T; Ferrarese F
Eur J Cancer; 2001 Mar; 37(5):591-6. PubMed ID: 11290434
[TBL] [Abstract][Full Text] [Related]
20. Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.
Joseph C; Macnamara O; Craze M; Russell R; Provenzano E; Nolan CC; Diez-Rodriguez M; Sonbul SN; Aleskandarany MA; Green AR; Rakha EA; Ellis IO; Mukherjee A
Br J Cancer; 2018 Apr; 118(8):1142-1151. PubMed ID: 29588513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
